Adherence
Intermittent empagliflozin administration (up to 14 days/month) improves dietary self-management and reduces energy intake in type 2 diabetes patients, achieving HbA1c and weight loss outcomes equivalent to daily administration.
For type 2 diabetes patients struggling with daily medication adherence or dietary control, an intermittent empagliflozin regimen (10mg, up to 14 days/month) may be a viable strategy. This approach allows patients to take the medication on days they perceive their diet was poor, potentially improving their overall dietary self-management and motivation. Clinical results (HbA1c and weight loss) were equivalent to daily dosing, suggesting that this flexible approach can maintain efficacy while reducing the burden of daily medication.
SGLT-2阻害薬の間欠療法では連日群に比して半分の内服であったにも関わらず、連日群と同等にHbA1cが改善し、有意な体重減少とQOLの上昇が得られた。間欠群でのみ食事摂取量が経時的に低下しており、食事療法に対する継続的なモチベーションの維持・向上が示唆され、結果として連日群と同等に血糖が改善したと考えられた。
Why this rating
Randomized controlled trial with clear endpoints, though sample size is small (n=50).
Source
Efficacy of intermittent empagliflozin supplementation on dietary self‐management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24‐week randomized controlled trial
Fukumi Yoshikawa et al. · Diabetes Obesity and Metabolism · 2018
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →